FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
Posted on 17 Nov 2026
Clinical laboratories use mass spectrometry for applications requiring highly sensitive and specific measurement, including steroid hormone measurement, vitamin D testing, and therapeutic drug monitoring. Traditional mass spectrometry methods often require specialized personnel and complex manual workflows, creating barriers to routine laboratory use. A newly authorized platform now brings mass spectrometry together with an automated, standardized workflow for routine clinical testing.
Roche has received U.S. Food and Drug Administration De Novo authorization for the cobas pro i 601 platform with the Ionify Gabapentin assay, components of its cobas® Mass Spec solution. The authorization expands Roche’s mass spectrometry menu into therapeutic drug monitoring. The U.S. menu also includes 25-Hydroxy Vitamin D total and steroid hormone testing assays, such as estradiol and 17-Hydroxyprogesterone.

The cobas Mass Spec solution combines the high specificity, sensitivity, and accuracy of mass spectrometry with an automated, standardized workflow. This configuration is designed to simplify testing that has traditionally been complex, while retaining the analytical capabilities associated with mass spectrometry. The Ionify Gabapentin assay adds a therapeutic drug monitoring application to the platform.
Roche will use an FDA-authorized Predetermined Change Control Plan to support future clinical mass spectrometry menu expansion. The authorized plan includes expansion of up to 22 Ionify assays on the cobas pro i 601 platform as requirements are met. These additional assays are not yet available and will be introduced in the future as applicable requirements are met.
“Some of the best diagnostic technologies are often very complex and, in the end, don't actually reach patients. Mass spectrometry has long been valued for its analytical performance, but the complexity of traditional workflows has limited its use in routine laboratories. By automating and standardizing this technology, we're helping make sophisticated testing more accessible to laboratories, clinicians and patients who depend on reliable results,” said Dan Malarek, President and CEO of Roche Diagnostics North America.







.jpg)